PharmaVentures acts as independent commercial expert with respect to Spectral MD’s IPO listing this month on London’s AIM

Oxford, UK, 29 June 2021: PharmaVentures is pleased to announce that it acted as an independent technical and commercial expert with respect to Spectral MD’s listing on London’s AIM on June 22nd.

Adrian Dawkes, Managing Director at PharmaVentures, said: “Through our expert knowledge across the medical device sector, and in particular the wound care market, we were pleased to be able to provide an independent expert assessment of Spectral’s DeepView® Wound Imaging System with respect to their Initial Public Offering (IPO) on AIM.”

Fintan Walton, Chief Executive of PharmaVentures, said: “Providing independent expert commercial and technical insight in healthcare is a key component in contributing to understanding investment opportunities including IPOs and other transactions. PharmaVentures has a long and strong history in providing valuable commercial insight to our clients because of our deep commercial knowledge of the healthcare sector.”

Marc Dudek, Director of Business and Corporate Development at Spectral MD, said: “Spectral MD is delighted to IPO on the AIM market. This funding will be used to support further development of our diabetic foot ulcer application and to initiate our expansion into the UK and...read more.